Haemophilia patient registry for children across Europe
Part of Blood & lymphatic, Genetic & congenital clinical trials.
This trial is a patient registry that collects medical information from children with hemophilia A or B. It may help care teams better understand bleeding patterns and treatments over time across participating hospitals.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have a diagnosis of hemophilia A or hemophilia B.
- Your blood clotting level (factor VIII or factor IX) is between 1% and 25%.
- Your medical records include complete details of factor treatment and bleeding episodes.
- You receive care at a hospital or clinic that participates in this registry.
- You can (or your parent/guardian can) provide consent to be included. “
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial is a research registry that enrolls children with hemophilia A or B to collect health information. It may help researchers better understand bleeding risk and treatment needs over time.
This study is a registry that collects information about people with bleeding disorders like hemophilia A or B and von Willebrand disease. The goal is to better understand these conditions and improve care across participating treatment centers.
This registry collects information from people with hemophilia who have had gene therapy, to track safety and how well it works over time. By joining, you help improve future treatments for others.
This trial tests a study medicine (marstacimab) for children with severe hemophilia A or B, to see if it can help prevent or reduce bleeding episodes. It may be an option for children who do not have certain other health conditions.
This study looks at how well a newer preventive treatment for hemophilia A works in everyday life. It collects real-world information from patients to help doctors tailor clotting therapy better.
This study looks at why the body sometimes stops responding to factor VIII treatment in hemophilia A. It aims to find patterns that help doctors predict and manage this, so they can keep the treatment working well.
Hear when a new Factor VIII Deficiency trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.